PRESENTATION TITLE

Early Interception in Multiple Myeloma


PRESENTER(S)

Irene M. Ghobrial, M.D., Professor of Medicine, Harvard Medical School, Director of Translational Research in the Department of Multiple Myeloma, Director of the Center for Prevention of Progression diseases (CPOP), Lavine Family Chair for Preventative Cancer Therapies, co-leader of the Lymphoma and Myeloma Program at Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, co-leader of the Stand Up to Cancer Myeloma Dream Team, and the recipient of the Claire W. and Richard P. Morse Research Award

PRESENTER BIO

Dr. Ghobrial completed her M.D. at Cairo University and a residency in Internal Medicine at Wayne State University in Detroit, Michigan, then trained as a Hematology/Oncology Fellow at the Mayo Clinic in Rochester, Minnesota. She is currently a Professor of Medicine and the Lavine Family Chair for Preventative Cancer Therapies at Dana-Farber Cancer Institute, Harvard Medical School. She is the Director of Translational Research in the Department of Multiple Myeloma, Director of the Center for Prevention of Progression diseases (CPOP), and co-leader of the Lymphoma and Myeloma Program at Dana-Farber. She is the co-leader of the Stand Up to Cancer Myeloma Dream Team—the first Dream Team award for blood cancer—and the recipient of the Claire W. and Richard P. Morse Research Award.

Her research focuses on identifying and developing effective therapeutic interventions for precursor conditions of myeloma (Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, MGUS and SMM). The focus of her research is to identify novel biomarkers of disease progression and develop potentially curative therapies in the pre-malignant phase that exploit the immune microenvironment in the bone marrow. She developed a large, patient-empowering observational study for these precursor conditions, the PCROWD study. She is also the PI of the first screening study for multiple myeloma in the US, the PROMISE study, which is currently screening 30,000 high-risk individuals, including those of African descent or with a family history of blood cancer.

VIEWING LOCATIONS
Zoom Registration Link

LEARNING OBJECTIVES

• Identifying the prevalence of MGUS in a high risk screened population.
• Defining mechanisms of disease progression in the tumor clone at the DNA and single cell RNA level.
• Examining mechanisms of immune regulation of disease progression at the single cell level.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.